- $35.25m
- -$10.36m
- $3.75m
- 18
- 28
- 58
- 26
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.64 | ||
| Price to Tang. Book | 0.64 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 9.41 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -55.78% | ||
| Return on Equity | -33.25% | ||
| Operating Margin | -990.84% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | 13.16 | 5.09 | 140.14 | 3.75 | 20.57 | 72.79 | 98.68% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
SCYNEXIS, Inc. is a biotechnology company. It is pioneering medicine to overcome and prevent difficult-to-treat and drug-resistant infections. It is developing its antifungal platform fungerps, a class of antifungal agents called triterpenoids, that are structurally distinct glucan synthase inhibitors and have shown in vitro and in vivo activity against a range of human fungal pathogens such as Candida and Aspergillus genera, including multidrug-resistant strains, as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and common mucorales species. Ibrexafungerp is the first representative of this class of antifungals with additional assets from the fungerp family under development, including SCY-247, which is in clinical stages of development. The United States Food and Drug Administration approved BREXAFEMME (ibrexafungerp tablets) for treatment of patients with vulvovaginal candidiasis, and for the reduction in the incidence of recurrent vulvovaginal candidiasis.
Directors
- Guy Macdonald NEC (62)
- Marco Taglietti PRE (61)
- Lawrence Hoffman CFO (67)
- Jim Maffezzoli VPR
- Nkechi Azie VPR
- Scott Sukenick GCN (43)
- David Angulo OTH (57)
- Christine Coyne OTH
- Armando Anido IND (63)
- Steven Gilman IND (68)
- Ann Hanham IND (69)
- David Hastings IND (59)
- Philippe Tinmouth IND (57)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- November 4th, 1999
- Public Since
- May 2nd, 2014
- No. of Shareholders
- 43
- No. of Employees
- 28
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
NASDAQ Global Market- Shares in Issue
- 38,981,064
- Address
- 1 Evertrust Plaza, 13Th Floor, JERSEY CITY, 07302-6548
- Web
- https://www.scynexis.com/
- Phone
- +1 2018845485
- Contact
- Irina Koffler
- Auditors
- Deloitte & Touche LLP
Upcoming Events for SCYX
SCYNEXIS Inc Annual Shareholders Meeting
Q2 2025 SCYNEXIS Inc Earnings Release
Similar to SCYX
111
NASDAQ Global Market
ADMA Biologics
NASDAQ Global Market
ANI Pharmaceuticals
NASDAQ Global Market
Aquestive Therapeutics
NASDAQ Global Market
Avadel Pharmaceuticals
NASDAQ Global Market
FAQ
What is the Scynexis share price?
As of Today at 23:06 UTC, shares in Scynexis are trading at $0.90. This share price information is delayed by 15 minutes.
How has the Scynexis share price performed this year?
Shares in Scynexis last closed at $0.90 and the price had moved by -36.32% over the past 365 days. In terms of relative price strength the Scynexis share price has underperformed the S&P500 Index by -40.12% over the past year.
What are the analyst and broker recommendations for Scynexis?
The overall consensus recommendation for Scynexis is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Scynexis dividend yield?
Scynexis does not currently pay a dividend.
Does Scynexis pay a dividend?
Scynexis does not currently pay a dividend.
When does Scynexis next pay dividends?
Scynexis does not currently pay a dividend.
How do I buy Scynexis shares?
To buy shares in Scynexis you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Scynexis?
As of the previous close price of $0.90, shares in Scynexis had a market capitalisation of $35.25m.
Where are Scynexis shares listed?
Here are the trading details for Scynexis:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: SCYX
What kind of share is Scynexis?
Based on an overall assessment of its quality, value and momentum Scynexis is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Scynexis share price forecast for 2025?
The analyst consensus target price for shares in Scynexis is $5.00. That is 452.91% above the last closing price of $0.90.
Analysts covering Scynexis currently have a consensus Earnings Per Share (EPS) forecast of -$0.32 for the next financial year.
Find out moreWhat is the trend in the Scynexis share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Scynexis. Over the past six months, its share price has underperformed the S&P500 Index by -37.37%.
As of the last closing price of $0.90, shares in Scynexis were trading -33.18% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Scynexis PE Ratio?
The Scynexis PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.90.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Scynexis?
Scynexis' management team is headed by:
- Guy Macdonald - NEC
- Marco Taglietti - PRE
- Lawrence Hoffman - CFO
- Jim Maffezzoli - VPR
- Nkechi Azie - VPR
- Scott Sukenick - GCN
- David Angulo - OTH
- Christine Coyne - OTH
- Armando Anido - IND
- Steven Gilman - IND
- Ann Hanham - IND
- David Hastings - IND
- Philippe Tinmouth - IND